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Anatomy and Pathology/Oncology
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PURPOSE. Intraocular medulloepithelioma (IM), the second most common primary neuroepithelial tumor of the eye, can lead to blindness in the affected eye and in rare cases, is deadly.
Intraocular medulloepithelioma lacks targetable biomarkers for potential pharmacologic
therapy. The purpose of this study was to identify actionable, tumor-specific proteins for
potential diagnostic or therapeutic strategies. We hypothesize that the tumor-specific
epigenetic enzyme EZH2 is selectively expressed in IM.
METHODS. We conducted a retrospective case series study of five IM from five eyes of four
children and one adult. Hematoxylin and eosin (H&E) stains of sections from formalin-fixed,
paraffin-embedded blocks of IM tumors were used to localize IM tumor cells in each case.
Using an EZH2-specific antibody for immunohistochemistry, we semiquantitatively calculated
the proportion of IM tumor cells positive for EZH2, and also assayed for EZH2 staining
intensity.
RESULTS. We found that EZH2 was expressed in all IM cases but this protein was absent in
nontumor ciliary body or retinal tissues. However, not all IM tumor cells expressed EZH2.
Similar to retinoblastoma, moderately to poorly differentiated (primitive appearing) IM tumor
cells strongly expressed EZH2; expression was weaker or absent in areas of well-formed
neuroepithelial units.
CONCLUSIONS. To our knowledge, this is the first study to identify an actionable tumor-specific
maker, EZH2, in IM. Our findings point to the possibility of exploring the potential of EZH2
inhibitors, already in clinical trials for other cancers, for IM.
Keywords: medulloepithelioma, epigenetics, EZH2

ntraocular medulloepithelioma (IM) is an uncommon primitive neoplasm that arises from the embryonic neuroepithelium that forms the ciliary body, iris, retina, or optic nerve
head.1 Intraocular medulloepithelioma is the second most
common primary intraocular cancer in childhood after
retinoblastoma, with an incidence of one case per 450,000 to
1,000,000.2 More than 80% of cases are diagnosed before 7
years of age.2 Intraocular medulloepithelioma can lead to
blinding complications, including cataract, retinal detachment,
and neovascular glaucoma.1 No standard of care exists for IM;
therapy can include brachytherapy, iridocyclectomy, or enucleation, depending on the size of the tumor, whether
extraocular extension exists, and vision at the time of

I

diagnosis.1 Unlike central nervous system (CNS) medulloepitheliomas, IMs rarely metastasize.1,3
Recently, new IM histopathologic biomarkers and genomic
alterations have been reported. Such biomarkers include CRX
and LIN28A, and recurrent mutations occur in DICER1 and
KMT2D genes.2,4,5 Nonetheless, the presence of these biomarkers or mutations does not point toward targeted therapies
that could potentially reduce the morbidity associated with
these tumors or treatments associated with them, such as
blindness from glaucoma or enucleation. To address these
unmet needs in IM as well as ocular/orbital/ocular adnexal
cancers in general, we have applied genetic and epigeneticbased precision medicine strategies to retinoblastoma,6 orbital
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TABLE. Summary of IM Cases
Case

Histologic Grade

% Nontumor
Retina/CB* (þ)

% Tumor (þ)

EZH2 Staining
Intensity

1

Well differentiated

0

>70% (Diffuse)

Moderate

2

Moderately differentiated

0

>70% (Diffuse)

Weak to moderate

3

Moderate to poorly differentiated

0

30%–70% (Moderate) Weak to moderate

4

Well differentiated with foci of
poor differentiation
Moderate to poorly differentiated

0

30%–70% (Moderate) Weak to moderate

5

0

>70% (Diffuse)

Moderate to strong

Notes (Including Age at Diagnosis)
Enucleation, left eye; 5-year-old female,
alive after 4 years
Enucleation, left eye; 53-year-old female,
died of metastatic disease
Enucleation, right eye; 9-year-old male,
alive after 18 years
Iridocyclectomy, right eye; 9-month-old
female, alive after 14 years
Enucleation after systemic chemotherapy,
left eye; 7-year-old male, chemotherapy
regimen per retinoblastoma protocol,
no subsequent followup available

* Refers to adjacent nontumor neural retina, RPE, ciliary body positive (þ) for EZH2 staining.

and ocular adnexal lymphoma,7 and cutaneous basal cell
carcinoma.8
In those reports,6–8 we discovered that the epigenetic
enzyme EZH2 is a key biomarker for aggressive forms of these
cancers, including retinoblastoma, which, like IM, arises from
neuroepithelial progenitor cells.5,6 EZH2, like KMT2D, is a
chromatin modifier that methylates lysine residues on histone
H3, which regulates gene expression, including tumor
suppressors and oncogenes.6 Gain of function EZH2 mutations
and EZH2 overexpression are frequent among cancers, and
several small molecule EZH2 inhibitors have recently entered
early phase clinical trials for nonophthalmic cancers such as
lymphoma and advanced solid tumors.2,7 The goal of the
current study is to explore whether the targetable epigenetic
protein EZH2 is specifically enriched IM.

METHODS
This study was approved by the University of Michigan (Ann
Arbor, MI, USA) institutional review board. Deidentified slides
from IM cases were sent from Wills Eye Hospital (Thomas
Jefferson University, Philadelphia, PA, USA) and Washington
University in St. Louis (MO, USA). Slides recut from archived,
paraffin-embedded, formalin-fixed blocks from one iridocyclectomy specimen and four enucleations for IM (four previously
untreated, one with previous treatment) were analyzed. Each
slide was stained with hematoxylin and eosin (H&E) and EZH2,
as previously described,6 and EZH2 staining was qualitatively
scored by two pathologists (SEA and AMS) on the basis of
proportion of nuclei with positive staining (<30%, focal; 30%–
70%, moderate; >70%, diffuse) and intensity (weak/moderate/
strong).

RESULTS
This report focuses on the histopathologic findings relating to
EZH2 immunohistochemistry in IM; limited clinical information (Table) was available for each case. All five IM tumors
showed classic hallmarks of IM, including multilaminar rosettes
or neurotubules, cords or festoons of cells, and small cellular
units that were either solid or displayed different-sized lumens,
surrounded by a loose mesenchymal tissue (Figs. 1, 2). EZH2
was present in each of the five tumors analyzed, and
histopathologic findings relating to tumor grade, proportion
of IM cells positive for EZH2 staining, and EZH2 staining
intensity are summarized in the Table. EZH2 staining was
restricted to IM cells, and was not present in any other cell

type, including the nontumor ciliary body epithelial cells,
neural retina, or retinal pigment epithelium (RPE; Figs. 1, 2).
For instance, EZH2-positive IM tumor cells formed epiretinal
membranes over EZH2-negative neural retina (Figs. 2A–D).
The proportion of IM cells staining positive for EZH2 was
moderate to diffuse in each case, but occasionally varied within
each tumor. EZH2 did not appear to mark all IM tumor cells.
Similar to our previously reported findings in retinoblastoma,
EZH2 appeared absent or only weakly positive in neuroepithelial units of the well-differentiated portions of the IM tumor,
but was diffusely and strongly positive in moderately to poorly
differentiated primitive/neuroblastic IM tumor cells (Figs. 1G,
1H). In the phthisical eye enucleated from a child with prior
chemotherapy and orbital extension of IM, small foci of
residual IM tumor cells are easily visible by EZH2 immunohistochemistry (Fig. 2E–H). Taken together, these data indicate
that EZH2 is specifically enriched in IM, both in primary
tumors and in a residual tumor after systemic chemotherapy.
Importantly EZH2 was never found in surrounding nontumor
tissues, such as neural retina, ciliary body, iris, and RPE cells.

DISCUSSION
To our knowledge, this is the first study to identify an actionable
target in IM, the second most common primary intraocular
cancer in children. This targetable epigenetic factor, EZH2, is a
histone methyltransferase that catalyzes formation of
H3K27me3, which is known to silence tumor suppressor gene
expression, thereby promoting tumorigenesis.6
In our recent report of EZH2 expression in retinoblastoma
(RB), we found that while EZH2 appears to be a specific
marker for RB, it did not mark all RB cells. We noted that EZH2
protein is low or absent in focal regions of photoreceptor
differentiation (e.g., fleurettes).6 Similarly, EZH2 does not mark
all IM tumor cells, and appeared to have a predilection for
moderately to poorly differentiated regions of the tumor. Why
might this be? Our recent work linking EZH2 expression to
normal fetal retinal development and retinoblastoma indicates
that this epigenetic marker does not distinguish among fetal
neuroretinal progenitor cells, retinoblastoma, and IM.4 Inasmuch as EZH2 is tightly linked to cellular proliferation,8 this
epigenetic enzyme may simply be enriched in retinal cells
undergoing rapid proliferation, which occurs during retinal
development and tumorigenesis.
Despite the sample size of five cases, our study is one of the
largest immunohistochemical series of IM to date, owing to the
fact that IM is quite rare.2–5 Our findings have two major
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FIGURE 1. EZH2 immunolocalization to IM tumor cells in the anterior segment. Each H&E (A, C, E, G) section is matched with corresponding,
EZH2-immunostained section (B, D, F, H). Insets in (A) and (B) correspond to high-power images in (C) and (D), respectively. (A, C) Enucleated
globe contains a ciliary body tumor (T); behind the lens (L), a neoplastic membrane is also seen. (B, D) EZH2 localizes to IM tumor cells in the ciliary
body. (E) In another enucleation specimen, neuroepithelial units extend posterior to the iris. (F) EZH2 is present in IM tumor (T) nuclei; the
remainder of brown pigment represents melanosomes in epithelial and stromal cells of the iris (I). (G) An iridocyclectomy specimen contains both
well-differentiated (WDT) and poorly differentiated, neuroblastic (PDT) regions of IM tumor. (H) The primitive, poorly differentiated portion of the
tumor exhibits greater EZH2 staining than the well-differentiated region. Scale bars: (A, B) 3 mm, (C–F) 300 lm. Magnification in (G, H) is 3100.

implications. One, EZH2 may serve as a diagnostic biomarker
to detect invasive IM tumor cells in the ciliary body, retina, iris,
and possibly optic nerve or extraocular tissues, similar to
retinoblastoma. Second, because EZH2 is specifically expressed in IM tumor cells, but not other nontumor cells,
EZH2 represents an attractive avenue for targeted therapy for
intraocular cancers. Indeed, we found that small molecule
EZH2 inhibitors related to those currently in early phase
clinical trials, uniquely target retinoblastoma tumor cells but
spare nontumor RPE cells in vitro. EZH2 inhibitors might have
a similar effect on IM cells; however, no in vitro or in vivo
models for IM exist. Future derivation of IM cell lines from
enucleated eyes or establishment of animal models with
conditional intraocular deletions of DICER1 or KMT2D could

enable a preclinical platform to test the efficacy of EZH2
inhibitors and other targeted strategies.2,6
The study of epigenetics in ocular and orbital diseases is in
its infancy. The recent discovery of recurrent mutations in
another histone methyltransferase, KMT2D, in IM highlights
the importance of epigenetics in the tumorigenesis of this
uncommon tumor.2 From studies of cancers in other parts of
the body, therapies that target tumor addiction to epigenetic
dysregulation, such as recurrent EZH2 overexpression or gain
of function mutations, have emerged as one of the most
promising strategies against cancer. For instance, in the last 2
years, several clinical studies (in the public domain, https://
clinicaltrials.gov/ct2/results?term¼ezh2) evaluating the use of
EZH2 as a biomarker or therapeutic target in lymphoma and a
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FIGURE 2. EZH2 immunolocalization to IM tumor cells in the posterior segment. Each H&E (A, C, E, G) section is matched with a corresponding,
EZH2-immunostained section (B, D, F, H). (A–D) Intraocular medulloepithelioma tumor cells have formed neoplastic epiretinal membranes (NM).
(B, D) EZH2 is present only in the neoplastic epiretinal membrane (NM) IM cell nuclei but is absent from nontumor retina (R). (E–H) Enucleated
globe from a case with previous systemic chemotherapy and extraocular extension shows IM tumor (T) as multicellular IM neuroepithelial units in
the subretinal space (SRS), anterior to the RPE. EZH2 localizes to IM tumor cells. Scale bars: (A–D) 300 lm, (E, F) 2 mm, (G, H) 200 lm.

variety of solid cancers have emerged. Our seminal studies
detailing EZH2 dysregulation in RB, orbital and ocular adnexal
lymphoma, and cutaneous basal cell carcinoma have uncovered ‘‘the tip of the iceberg’’ of the potential of using
epigenetics to better understand how ocular, ocular adnexal,
and orbital tumors form, and to develop novel therapeutics.6–8
Taken together, this study indicates EZH2 is a biomarker for IM,
and highlights the possibility that EZH2 could be exploited as a
therapeutic target for this pediatric tumor, a cancer that lacks
biologically targeted treatments.
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